CEL-SCI Corporation (CVM)
CVMAMEXBiotechnology: Biological Products (No Diagnostic Substances)
$1.41
+0.0600 (+4.44%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $24.62m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8900 to $7.80
- Average volume
- 579.9k
- Previous close
- $1.35
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$6.03m | -$5.37m | -$5.33m | -$5.56m |
| Net income | -$6.10m | -$5.47m | -$5.47m | -$5.67m |
News
7 latest- CEL-SCI (CVM) Price Target Decreased by 91.67% to 25.50Fintel · Feb 4, 2026
- Monday 1/26 Insider Buying Report: BDSX, CVMBNK Invest · Jan 26, 2026
- After-Hours Trading Sees Sharp Gains Across Emerging Growth Names RTTNews · Sep 19, 2025
- CEL-SCI Corp. Prices Public Offering Of 1.11 Mln Shares At $9.00/shr RTTNews · Aug 27, 2025
- Monday 7/28 Insider Buying Report: CVM, LOOPBNK Invest · Jul 28, 2025
- CEL-SCI Implements 1-for-30 Stock Split To Support Share Price RTTNews · May 20, 2025
- Biotech Alert: Searches spiking for these stocks todayTipRanks · Jan 2, 2025
The company
CEL-SCI believes that boosting a patients immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system'target' the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been administered to over 740 patients and has an excellent safety profile compared to other cancer drugs. It has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- Region
- North America
- Website
- cel-sci.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.